Navigation Links
Anesiva Announces New Zingo Marketing and Distribution Agreement
Date:4/29/2008

most common adverse events with Zingo were redness (erythema), red dots (petechiae) and swelling (edema). In March 2008, Anesiva submitted a supplemental new drug application (sNDA) to expand the label indication for Zingo to include adults, based on a positive Phase 3 trial in nearly 700 patients.

About Anesiva and its Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA, USA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
2. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
3. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
4. Anesiva Appoints Daniel Janney to Board of Directors
5. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
6. Anesiva Announces Completion of Common Stock Offering
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
10. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
(Date:7/23/2014)... Emirates (UAE) (PRWEB) July 23, 2014 ... recently announced that its biobanking project, Provia ... Ph.D. to its growing Advisory Board. Scott Wolf ... pleased to have Dr. Vaught onboard with Provia’s ever-expanding ... and expertise that Provia’s management team brings to this ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4
... YORK, June 8, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0548785/Future-of-White-Biotechnology-in-China.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... referred to the third wave in biotechnology, ...
... 7, 2011 Vaxart, Inc., a San Francisco biotechnology company ... I clinical trial. This is the first clinical study evaluating ... The trial site is in the United States. ... is demonstrated with one vaccine, we can expect that later ...
... 7, 2011 Infrared Systems International (OTCBB: IFRS) is pleased ... pilot study of its NatuRx™ HIV/AIDS treatment and will push ... AquaLiv concluded a pilot study with two HIV/AIDS patients ... of the first reported AIDS victims on June 5th, 1981. ...
Cached Biology Technology:Reportlinker Adds Future of White Biotechnology in China 2Reportlinker Adds Future of White Biotechnology in China 3Reportlinker Adds Future of White Biotechnology in China 4Reportlinker Adds Future of White Biotechnology in China 5Vaxart Begins First Oral Vaccine Clinical Trial 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 3
(Date:7/24/2014)... brewery has its own microbial terroir, meaning the microbial ... found in the product, creating the final flavor according ... Applied and Environmental Microbiology . This is the ... a sake brewery. , Many sake makers inoculate ... A. Mills of the University of California, Davis, but ...
(Date:7/24/2014)... cleanup experts gathered at NJIT this week for an ... the U.S. Environmental Protection Agency (EPA) to dredge toxic ... River. , The EPA has called the plan, which ... and capping sections of the riverbed, one of the ... would be dredged and disposed off-site. , "We need ...
(Date:7/24/2014)... research into the potato genes that best adapt to ... in rainfall and increased extremes of hot and cold ... in order to create new potato varieties that will ... seeking to find out how the current potato varieties ... higher and lower temperatures. , This research is part ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2
... Mich.---By mimicking the structure of the silk moth,s antenna, ... better nanopore---a tiny tunnel-shaped tool that could advance understanding ... A paper on the work is newly published ... headed by Michael Mayer, an associate professor in the ...
... developed by researchers in Temple University,s College of Science ... cancer. The leptin receptor antagonist peptide, developed by ... attractive option for triple negative breast cancer treatment, especially ... their findings online in the European Journal of ...
... environmental researchers from across North America have been ... Based at Stanford University,s Woods Institute for the ... 1998 to help academic scientists make their knowledge ... program selects up to 20 mid-career academic environmental ...
Cached Biology News:Silk moth's antenna inspires new nanotech tool with applications in Alzheimer's research 2New peptide could be effective treatment for triple negative breast cancer 220 researchers selected as 2011 Leopold Leadership Fellows 220 researchers selected as 2011 Leopold Leadership Fellows 320 researchers selected as 2011 Leopold Leadership Fellows 4
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... electronic from BRAND adds ergonomics and ... the only electronic, motor-driven repeating pipette ... including BRAND PD-Tip syringe tips, Eppendorf ... Tips,and VWRbrand Combi-Syringes. Select virtually any ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Biology Products: